1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Celecoxib Capsules

Trade Name: CELEBREX, CELEBRA, CELEBRA MAX, SOLEXA, CELORA, ACLARIX, ACLAREX, ARTILOG, ARTRID, CELECOX, VALDYNE, VALDYN, CAPSURE, CELATRIT, KUDEQ, SYRIBEX, DICOXIBE, IGEF

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Specific target organ systemic toxicity (repeated exposure): Category 2
Chronic aquatic toxicity: Category 1

EU Classification:

EU Indication of danger: Toxic to reproduction, Category 2
Harmful

EU Risk Phrases:

R61 - May cause harm to the unborn child.
R53 - May cause long-term adverse effects in the aquatic environment.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Label Elements

Signal Word: Danger

Hazard Statements:
H360D - May damage the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure
H410 - Very toxic to aquatic life with long lasting effects

SAFETY DATA SHEET

Revised date: 09-Mar-2015
Version: 4.4
Page 1 of 10

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
1-212-573-2222

Contact E-Mail: pfizer-MSDS@pfizer.com
Precautionary Statements:

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards
Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celecoxib</td>
<td>169590-42-5</td>
<td>Not Listed</td>
<td>Rep. Cat.2; R61 Xn; R48/22 R53</td>
<td>STOT RE 2, H373; Aquatic Chronic 1, H410; Repr. 1B, H360D</td>
<td>74</td>
</tr>
<tr>
<td>Sodium Lauryl Sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Povidone</td>
<td>9003-39-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>74811-65-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Celecoxib
Pfizer OEL TWA-8 Hr: 1000µg/m³

Magnesium stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Exposure Controls
Engineering Controls: General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes: Wear safety glasses or goggles if eye contact is possible.
Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule
Color: White and blue, gold or green
Odor: No data available.
Odor Threshold: No data available.
Molecular Formula: Mixture
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Celecoxib
Measured Log P 3.53
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Data Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decomposition Temperature (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Pressure (kPa)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml)</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Data Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>No data available</td>
</tr>
<tr>
<td>Chemical Stability</td>
<td>Stable under normal conditions of use.</td>
</tr>
<tr>
<td>Possibility of Hazardous Reactions</td>
<td>No data available</td>
</tr>
<tr>
<td>Oxidizing Properties</td>
<td>No data available</td>
</tr>
<tr>
<td>Conditions to Avoid</td>
<td>Fine particles (such as dust and mists) may fuel fires/explosions.</td>
</tr>
<tr>
<td>Incompatible Materials</td>
<td>As a precautionary measure, keep away from strong oxidizers</td>
</tr>
<tr>
<td>Hazardous Decomposition Products</td>
<td>No data available</td>
</tr>
</tbody>
</table>

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause minimal eye irritation (based on animal data). May cause allergic reaction in sensitive individuals.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, kidneys, and the developing fetus.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including gastrointestinal effects such as nausea, pain, heartburn, bleeding, ulceration, and perforation. Serious allergic reactions, including anaphylaxis, have been reported. Clinical use of this drug has caused swelling of face/extremities, hives, redness and swelling of the skin (urticaria), skin rash, chills yellowing of skin and eyes, headache, dizziness, vomiting, diarrhea, insomnia, increase in blood pressure (hypertension), respiratory infection, chest pain, heart attack (myocardial infarction), stroke, congestive heart failure, liver effects, kidney effects, changes in blood cell levels. Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). It may also cause prolonged bleeding time.
11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Celecoxib
- Rat Oral LD 50 > 2000 mg/kg
- Dog Oral LD 50 > 2000 mg/kg

Povidone
- Rat Oral LD50 100 g/kg

Magnesium stearate
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

Sodium Lauryl Sulfate
- Rat Oral LD 50 1288 mg/kg
- Rat Sub-tenon injection (eye) LD 50 210mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Celecoxib
- Skin Irritation Rabbit No effect
- Eye Irritation Rabbit Minimal
- Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Celecoxib
- 13 Week(s) Rat Oral 20 mg/kg/day NOAEL Kidney, Gastrointestinal System
- 13 Week(s) Dog Oral 35 mg/kg/day NOAEL Gastrointestinal system
- 6 Month(s) Rat Oral 20 mg/kg/day NOAEL Gastrointestinal system, Kidney
- 12 Month(s) Dog Oral 35 mg/kg/day NOAEL Gastrointestinal system

Sodium Lauryl Sulfate
- 3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Celecoxib
- Embryo / Fetal Development Rat Oral 50 mg/kg/day LOAEL Fetotoxicity
- Embryo / Fetal Development Rabbit Oral 100 mg/kg/day LOAEL Fetotoxicity
- Embryo / Fetal Development Rat Oral 30 mg/kg/day LOAEL Teratogenic
- Embryo / Fetal Development Rabbit Oral 60 mg/kg/day NOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Celecoxib
- Bacterial Mutagenicity (Ames) Salmonella Negative
- Mammalian Cell Mutagenicity HGPRT Negative
- Direct DNA Interaction Not applicable Negative
### 11. TOXICOLOGICAL INFORMATION

**In Vitro Cytogenetics**
- Chinese Hamster Ovary (CHO) cells: Negative

**In Vivo Micronucleus**
- Not applicable: Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

- **Celecoxib**
  - 2 Year(s)  Rat  Oral  200 (M), 10 (F) mg/kg/day  NOAEL  Not carcinogenic
  - 2 Year(s)  Mouse  Oral  25 (M), 50 (F) mg/kg/day  NOAEL  Not carcinogenic

**Carcinogen Status:**
- None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

**Povidone**
- IARC: Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:**
- The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See Aquatic toxicity data of the active ingredient, below.

**Toxicity:**

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

- **Celecoxib**
  - *Daphnia magna* (Water Flea)  TAD  EC50  48 Hours  > 1.5 mg/L
  - *Pimephales promelas* (Fathead Minnow)  TAD  LC50  96 Hours  >1.2 mg/L
  - *Selenastrum capricornutum* (Green Alga)  TAD  NOEC  12 Days  0.11 mg/L
  - *Microcystis aeruginosa* (Blue-green Alga)  TAD  NOEC  14 Days  0.089 mg/L
  - *Ceriodaphnia dubia* (Daphnids)  TAD  NOEC  7 Days  0.17 mg/L
  - *Pimephales promelas* (Fathead Minnow)  OECD  NOEC  33 Days  0.23 mg/L
  - *Daphnia magna* (Water Flea)  EPA  NOEC  21 Days  0.06 mg/L

**Aquatic Toxicity Comments:**
- A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

**Bacterial Inhibition: (Inoculum, Method, End Point, Result)**

- **Celecoxib**
  - *Trichoderma viride* (Fungus)  TAD  MIC  > 1000 mg/L

**Persistence and Degradability:**
- No data available

**Bio-accumulative Potential:**
- No data available

**Mobility in Soil:**
- No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077
UN proper shipping name: Environmentally Hazardous Substance, Solid, n.o.s (celecoxib)
Transport hazard class(es): 9
Packing group: III
Environmental Hazard(s): Marine Pollutant

5 kg/L Exception: Effective January 1, 2015, UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not regulated as dangerous goods for transport by any mode:
* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.
* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A
Class D, Division 2, Subdivision B

Celecoxib
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: Not Listed
15. REGULATORY INFORMATION

Povidone
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Lactose NF, monohydrate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: Not Listed

Sodium Lauryl Sulfate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 6
- EU EINECS/ELINCS List: 205-788-1

Crocarmellose sodium
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Magnesium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Toxic to Reproduction: Category 2
Xn - Harmful

R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 14 - Transport Information.

Revision date: 09-Mar-2015
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet